Literature DB >> 6890355

Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents.

H J Keller, B Keppler, D Schmähl.   

Abstract

The antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds against Walker 256 carcinosarcoma in comparison to cis-dichlorodiammineplatinum(II) (cisplatin, cis-DDP, NSC 119875) was investigated. The tested compounds showed in this experimental model an enhanced median survival time and a lower toxicity compared to cisplatin.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6890355

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN： 0004-4172


  9 in total

1.  Novel enantiopure cyclopentadienyl Ti(IV) oximato compounds as potential anticancer agents.

Authors:  Isabel de la Cueva-Alique; Laura Muñoz-Moreno; Yosra Benabdelouahab; Benelita T Elie; Mohammed Amin El Amrani; Marta E G Mosquera; María Contel; Ana M Bajo; Tomás Cuenca; Eva Royo
Journal:  J Inorg Biochem       Date:  2015-12-09       Impact factor: 4.155

2.  Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III). A representative of a new class of inorganic antitumor agents.

Authors:  B K Keppler; W Rupp
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Efficacy of beta-diketonato complexes of titanium, zirconium, and hafnium against chemically induced autochthonous colonic tumors in rats.

Authors:  H Bischoff; M R Berger; B K Keppler; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

4.  Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats.

Authors:  M H Seelig; M R Berger; B K Keppler
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane.

Authors:  T Schilling; K B Keppler; M E Heim; G Niebch; H Dietzfelbinger; J Rastetter; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

6.  Antitumor properties of organometallic metallocene complexes of tin and germanium.

Authors:  P Köpf-Maier; C Janiak; H Schumann
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  Ionic titanocene complexes: a new type of antitumor agent.

Authors:  P Köpf-Maier; E Neuse; T Klapötke; H Köpf
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats.

Authors:  F T Garzon; M R Berger; B K Keppler; D Schmähl
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors.

Authors:  S Frühauf; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.